Comparative Pharmacology
Head-to-head clinical analysis: NABUMETONE versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NABUMETONE versus ONMEL.
NABUMETONE vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA), is responsible for its therapeutic effects.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
1000 mg orally once daily with food; may increase to 1500-2000 mg/day in divided doses if needed.
50 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life is approximately 22-30 hours in healthy adults, allowing once-daily dosing. Steady state is achieved after 3-5 days.
Clinical Note
moderateNabumetone + Gatifloxacin
"Nabumetone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNabumetone + Rosoxacin
"Nabumetone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNabumetone + Levofloxacin
"Nabumetone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNabumetone + Trovafloxacin
"Nabumetone may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Approximately 80% of a dose is excreted in urine as metabolites (primarily 6-methoxy-2-naphthylacetic acid and its glucuronide conjugates), with about 10% excreted in feces. Biliary excretion is minimal.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID